(Q47173372)

11 January 2018

title

Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes (English)

1 reference

11 January 2018

1 reference

1 reference

3

1 reference

11 January 2018

Hans-Ulrich Häring

4

object named as

H-U Häring

1 reference

11 January 2018

author name string

T Heise

1

1 reference

11 January 2018

L Morrow

2

1 reference

11 January 2018

C Kapitza

5

1 reference

11 January 2018

M Abt

6

1 reference

11 January 2018

M Ramsauer

7

1 reference

11 January 2018

M-C Magnone

8

1 reference

11 January 2018

S Fuerst-Recktenwald

9

1 reference

11 January 2018

publication date

9 June 2014

1 reference

11 January 2018

Diabetes, Obesity and Metabolism

published in

1 reference

11 January 2018

volume

16

1 reference

11 January 2018

issue

11

1 reference

11 January 2018

page(s)

1070-1077

1 reference

11 January 2018

Management of diabetes across the course of disease: minimizing obesity-associated complications

cites work

1 reference

Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects

21 January 2018

1 reference

Therapeutic targets to reduce cardiovascular disease in type 2 diabetes

21 January 2018

1 reference

Endocrine function in human obesity

21 January 2018

1 reference

Mechanisms involved in the side effects of glucocorticoids

21 January 2018

1 reference

Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase

21 January 2018

1 reference

Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice

21 January 2018

1 reference

A transgenic model of visceral obesity and the metabolic syndrome

21 January 2018

1 reference

Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice

21 January 2018

1 reference

The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy

21 January 2018

1 reference

Clinical Safety, Pharmacokinetics, and Pharmacodynamics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 in Healthy Volunteers and Elderly Adults

21 January 2018

1 reference

Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome.

21 January 2018

1 reference

11β-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects

21 January 2018

1 reference

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

21 January 2018

1 reference

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition

21 January 2018

1 reference

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation

21 January 2018

1 reference

11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12317

1 reference

11 January 2018

PubMed ID

24828020

1 reference

11 January 2018